Disease · MONDO_0005937

REM sleep behavior disorder

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. REM sleep behavior disorder. Diseases, record MONDO_0005937. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005937

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: REM sleep behavior disorder; Open Targets
Open Targets ID: MONDO_0005937; Open Targets
Other names: Rapid eye movement sleep behavior disorder; Open Targets
Disease Ontology: DOID:9091; Disease Ontology
MeSH: D020187; MeSH
Highest stage of its drugs: Phase 2, for 5 of its 6 drugs, from ClinicalTrials.gov; Open Targets

Drugs6

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CLONAZEPAM	CHEMBL452	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
MELATONIN	CHEMBL45	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
NELOTANSERIN	CHEMBL598172	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
CLENBUTEROL	CHEMBL49080	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
NADOLOL	CHEMBL521606	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
TASIMELTEON	CHEMBL2103822	Small molecule	Early phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets21

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ADRB2	Beta-2 adrenergic receptor	2	Beta-2 adrenergic receptor agonist; Beta-2 adrenergic receptor antagonist	Phase 2	https://conductscience.org/library/genes/154	Drugs and targets
MTNR1A	Melatonin receptor	2	Melatonin receptor agonist	Phase 2	https://conductscience.org/library/genes/4543	Drugs and targets
MTNR1B	Melatonin receptor	2	Melatonin receptor agonist	Phase 2	https://conductscience.org/library/genes/4544	Drugs and targets
ADRB1	Beta-1 adrenergic receptor	1	Beta-1 adrenergic receptor antagonist	Phase 2	https://conductscience.org/library/genes/153	Drugs and targets
GABRA1	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel positive allosteric modulator	Phase 2	https://conductscience.org/library/genes/2554	Drugs and targets
GABRA2	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel positive allosteric modulator	Phase 2	https://conductscience.org/library/genes/2555	Drugs and targets
GABRA3	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel positive allosteric modulator	Phase 2	https://conductscience.org/library/genes/2556	Drugs and targets
GABRA4	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel positive allosteric modulator	Phase 2	https://conductscience.org/library/genes/2557	Drugs and targets
GABRA5	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel positive allosteric modulator	Phase 2	https://conductscience.org/library/genes/2558	Drugs and targets
GABRA6	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel positive allosteric modulator	Phase 2	https://conductscience.org/library/genes/2559	Drugs and targets

1 to 10 of 21

See all 21 targets

Trials7

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT04739423	A Study of Clenbuterol (CST-103) Co-administered With Nadolol (CST-107) in Subjects With Neurodegenerative Disorders	Phase 2	41	2024-12-02	Mild Cognitive Impairment, Lewy Body Dementia, Parkinson's Disease Rapid Eye Movement Sleep Behavior Disorder, Parkinson's Disease Dementia	CLENBUTEROL, NADOLOL	Its record names the disease	ClinicalTrials.gov
NCT02708186	Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)	Phase 2	34	2020-05-20	Dementia With Lewy Bodies, REM Sleep Behavior Disorder, Parkinson's Disease Dementia	NELOTANSERIN	Its record names the disease	ClinicalTrials.gov
NCT02871427	Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder	Phase 2	80		Lewy Body Dementia, Dementia With Lewy Bodies, Parkinson's Disease Dementia, Visual Hallucinations, REM Sleep Behavior Disorder	NELOTANSERIN	Its record names the disease	ClinicalTrials.gov
NCT02312908	Effect of Clonazepam on REM Sleep Behavior Disorder in Patients With Parkinsonism	Phase 2	40		REM Sleep Behavior Disorder	CLONAZEPAM	Its record names the disease	ClinicalTrials.gov
NCT03255642	Efficacy and Safety of Melatonin and Clonazepam for IRBD	Not applicable	34		REM Sleep Behavior Disorder	CLONAZEPAM, MELATONIN	Its record names the disease	ClinicalTrials.gov
NCT02789592	Efficacy and Safety of Melatonin PR and Clonazepam in Patients With REM Sleep Behavior Disorder in Parkinson Disease	Phase 2	30		REM Sleep Behavior Disorder, Parkinson Disease	CLONAZEPAM, MELATONIN	Its record names the disease	ClinicalTrials.gov
NCT05922995	The Effects of Tasimelteon in Participants With REM Behavior Disorder (RBD)	Early phase 1	20		REM Behavior Disorder	TASIMELTEON	Open Targets' reading of its record	ClinicalTrials.gov

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Nelotanserin vs Placebo: deaths from any cause	0 of 16	0 of 18	34	NCT02708186	Trial comparisons
Nelotanserin vs Placebo: serious adverse events	2 of 16	0 of 18	34	NCT02708186	Trial comparisons

Papers from its trials2

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
35141811	DERIVED	1	PubMed
33714847	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005937

GET https://conductscience.org/api/diseases/v1/MONDO_0005937/targets?page=2

API reference For AI assistants